Evidence for dopaminergic modulation of pancreatic polypeptide secretion in man.
This study examines the role of dopaminergic mechanisms in the regulation of human pancreatic polypeptide (hPP) secretion in 11 normal male volunteers. Administration of domperidone (20 mg iv), an extracerebral inhibitor of dopamine receptors, resulted in a hPP rise (p less than 0.05) within 10 min and a peak response (p less than 0.01) at 15 min after drug administration. Administration of the dopaminergic agonist, bromocriptine, 2.5 mg tid for 4 days eliminated hPP responses to isometric handgrip exercise in these 11 volunteers. These results suggest that dopaminergic mechanisms may exert a tonic inhibitory effect on hPP secretion in normal subjects.
D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology*; D004294:Domperidone / Q000494:pharmacology*; D018492:Dopamine Antagonists; D006801:Humans; D007537:Isometric Contraction; D008297:Male; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D011187:Posture; D011954:Receptors, Dopamine / Q000502:physiology*
D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D001971:Bromocriptine; D004294:Domperidone; D010191:Pancreatic Polypeptide